Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (Nasdaq: RVMD) reported that EMA’s CHMP has begun a phased review of daraxonrasib for pancreatic cancer, aiming to accelerate assessment before a full marketing application.
Daraxonrasib has EMA orphan drug status, Cancer Medicines Pathfinder priority, and a rolling NDA submission to the U.S. FDA nearing completion, supported by positive Phase 3 RASolute 302 data.
Revolution Medicines (Nasdaq: RVMD) reported Phase 1/2 data for zoldonrasib combinations in RAS G12D metastatic pancreatic cancer at ESMO GI 2026.
First-line zoldonrasib plus chemotherapy showed ORR up to 82%, while zoldonrasib plus daraxonrasib in pretreated patients showed ORR of 47–50%, supporting pivotal Phase 3 RASolute 305 and 309 trials.
Revolution Medicines (RVMD) will present new clinical data from its RAS(ON) inhibitor combination trials in pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026, July 1–4 in Munich.
The program features two Phase 1/2 zoldonrasib combination orals and two Phase 3 RASolute trial posters in PDAC.
Revolution Medicines (RVMD) has begun treating patients in RASolute 305, a global randomized Phase 3 trial of zoldonrasib plus standard chemotherapy as first line treatment for metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC).
The double-blind, placebo-controlled study compares zoldonrasib plus investigator’s choice of modified FOLFIRINOX or gemcitabine plus nab-paclitaxel versus placebo plus chemotherapy. Primary endpoints are progression-free survival and overall survival, with key secondary endpoints including antitumor activity, safety, tolerability, and patient-reported outcomes.
Revolution Medicines (Nasdaq: RVMD) announced a planned leadership transition for Steve Kelsey, M.D., president of R&D. Effective July 1, 2026, he becomes senior advisor to the CEO, with retirement planned for January 4, 2027, and anticipated appointment to the board.
The company will adopt a new R&D leadership structure, with Alan Sandler, M.D. overseeing development, Jan Smith, Ph.D. leading research, and Xiaolin Wang, Sc.D. serving as executive vice president, integrated portfolio strategy and management.
Revolution Medicines (Nasdaq: RVMD) reported pivotal Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma.
Daraxonrasib reduced risk of death by 60% (HR 0.40), doubled median OS to 13.2 vs ~6.6–6.7 months, improved PFS and response rates, and showed a generally manageable safety profile versus chemotherapy. The company plans global regulatory filings and has an FDA-authorized expanded access program.
Revolution Medicines (Nasdaq: RVMD) will host a live investor webcast on Sunday, May 31, 2026 at 7:00 p.m. ET to discuss positive Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), following presentation at the 2026 ASCO Annual Meeting.
The webcast and a replay (available for at least 14 days) can be accessed via the company’s investor relations events and presentations webpage.
Revolution Medicines (NASDAQ: RVMD) announced that the New England Journal of Medicine published Phase 1/2 data for daraxonrasib in previously treated metastatic RAS‑mutant pancreatic ductal adenocarcinoma (PDAC). The published results supported initiation of the global Phase 3 registrational trial RASolute 302.
According to the company, Phase 1/2 data showed clinical antitumor activity, durable responses, and an acceptable safety profile; the company also announced positive topline RASolute 302 results reporting an overall survival benefit versus standard cytotoxic chemotherapy.
Revolution Medicines (Nasdaq: RVMD) reported Q1 2026 results and clinical progress on May 6, 2026. Key highlights: daraxonrasib showed a median overall survival of 13.2 months vs 6.7 months (HR 0.40; p<0.0001) in Phase 3 RASolute 302 for previously treated PDAC, with plans to submit to global regulators and present at ASCO.
The company closed concurrent financings raising $2.225 billion gross, holds $1.9 billion cash (Mar 31) and received approximately $2.1 billion net in April; updated 2026 GAAP operating expense guidance is $1.7–$1.8 billion.
Revolution Medicines (Nasdaq: RVMD) will report first-quarter 2026 financial results on May 6, 2026 after market close. A live webcast with senior management will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and corporate progress.
The live webcast and an archived replay (available for at least 14 days) can be accessed via the company's investor events and presentations page.